EP 2 139 494 B1 relates to pharmaceutical formulations containing dapaglifozin (Forxiga™) propylene glycol hydrate.
Brief outline of the case
The patent was opposed by 6 opponents and the OD revoked the patent.
The board set aside the OD’s decision as it had committed a SPV.
The proprietor requested a different apportionment of costs which was refused by the board.